Suero Molina Eric, van Eck Albertus T C J, Sauerland Cristina, Schipmann Stephanie, Horstmann Gerhard, Stummer Walter, Brokinkel Benjamin
Department of Neurosurgery, University Hospital Münster, Münster, Germany.
Gamma Knife Center Krefeld, Krefeld, Germany.
World Neurosurg. 2019 Feb;122:e1240-e1246. doi: 10.1016/j.wneu.2018.11.022. Epub 2018 Nov 14.
The use of Gamma Knife radiosurgery (GKRS) for recurrent or residual vestibular schwannoma (VS) after microsurgery (MS) has been investigated in several retrospective studies. The purpose of this study was to identify potential risk factors for both neurologic deterioration and tumor progression after GKRS for previously operated VSs in a prospective setting.
Patients who underwent GKRS for previously operated and histopathologically confirmed VS between 1998 and 2015 were prospectively followed-up. Risk factors for therapy side effects and predictors for tumor control were investigated in uni- and multivariate analyses.
A total of 160 individuals with a median age of 55 years were included. Median tumor volume prior to GKRS was 1.40 cm (range, 0.06-35.80 cm). After a median follow-up of 36 months, hearing and facial nerve function were serviceable (modified Gardner-Robertson and House-Brackmann grades I and II) in 7 (5%) and 82 (55%) patients, respectively. Deterioration to a nonserviceable facial nerve function after GKRS was found in 3% (3/89) and tended to increase with rising tumor volume (odds ratio, 1.65 per cm; 95% confidence interval, 1.00-2.71; P = 0.051). Median tumor volume prior to GKRS was higher in patients with radiologic (P = 0.020) or clinical tumor progression (P < 0.001). Critical tumor volume prior to GKRS to predict clinical and radiologic tumor progression was 1.30 cm (P < 0.001) and 3.30 cm (P = 0.019), respectively. However, in multivariate analyses, none of the analyzed variables were found to independently predict tumor progression.
Intended submaximal resection followed by GKRS is a viable treatment for VS. Because tumor remnant size after MS is an important predictor for recurrence after adjuvant GKRS, both brainstem and cerebellar decompression and maximal safely achievable resection should remain major goals of microsurgery.
多项回顾性研究对伽玛刀放射外科手术(GKRS)用于显微手术(MS)后复发或残留的前庭神经鞘瘤(VS)进行了调查。本研究的目的是在一项前瞻性研究中确定GKRS治疗既往手术的VS后神经功能恶化和肿瘤进展的潜在风险因素。
对1998年至2015年间因既往手术且经组织病理学证实为VS而接受GKRS治疗的患者进行前瞻性随访。在单因素和多因素分析中研究治疗副作用的风险因素和肿瘤控制的预测因素。
共纳入160例患者,中位年龄55岁。GKRS治疗前肿瘤中位体积为1.40 cm(范围0.06 - 35.80 cm)。中位随访36个月后,分别有7例(5%)和82例(55%)患者的听力和面部神经功能良好(改良Gardner - Robertson分级和House - Brackmann分级为I级和II级)。GKRS治疗后3%(3/89)的患者出现面部神经功能恶化至失用,且有随肿瘤体积增大而增加的趋势(优势比,每厘米1.65;95%置信区间,1.00 - 2.71;P = 0.051)。放射学(P = 0.020)或临床肿瘤进展(P < 0.001)的患者GKRS治疗前的肿瘤中位体积更高。预测临床和放射学肿瘤进展的GKRS治疗前临界肿瘤体积分别为1.30 cm(P < 0.001)和3.30 cm(P = 0.019)。然而,在多因素分析中,未发现任何分析变量能独立预测肿瘤进展。
意向性次全切除后行GKRS是VS的一种可行治疗方法。由于MS后肿瘤残留大小是辅助GKRS治疗后复发的重要预测因素,脑干和小脑减压以及最大安全可切除范围仍应是显微手术的主要目标。